- Webinar to feature presentations from
Kelly E. Dunn, PhD, MBA, and
Stuart Gitlow, MD, MPH, MBA, on
Thursday, May 19 at 11:00am EDT -
NEW YORK, May 12, 2022 /PRNewswire/ -- Mind
Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the
"Company" or "MindMed"), a clinical stage biopharmaceutical company
developing novel products to treat brain health disorders, today
announced that it will host a key opinion leader (KOL) webinar on
substance use disorders and withdrawal management on Thursday, May 19, 2022 at 11:00am EDT.
The webinar will feature presentations from key opinion leaders
Kelly E. Dunn, PhD, MBA
(Johns Hopkins School of Medicine) and
Stuart Gitlow, MD, MPH, MBA (Past
President of the American Society of Addiction Medicine) who will
discuss substance use disorders, the current treatment landscape
for opioid use disorder, and the unmet medical need in the
management of opioid withdrawal.
Following presentations by Drs. Dunn and Gitlow, the MindMed
leadership team will provide an overview of the MM-110 (zolunicant)
clinical development program and discuss its therapeutic potential
in substance use disorders. MM-110 is an α3β4 nicotinic cholinergic
receptor antagonist that offers a novel mechanism to address a
critical gap in current opioid use disorder treatment.
A live question and answer session will follow the formal
presentation. To register for the event, please click here.
- Kelly E. Dunn, PhD, MBA is an
Associate Professor in the Behavioral Pharmacology Research Unit
within the Department of Psychiatry and Behavioral Sciences in the
Johns Hopkins University School of
Medicine. Dr. Dunn has worked in the area of opioid use
disorder treatment and withdrawal mitigation since 2005 and has
served as the Principal Investigator on grants. Dr. Dunn earned her
PhD in Human Behavioral Pharmacology from the University of Vermont, her MS in Applied
Biopsychology from the University of New
Orleans and her MBA from the Johns Hopkins Carey School of
Business.
- Stuart Gitlow, MD, MPH, MBA is
Past President of the American Society of Addiction Medicine and
Past Chair of the AMA's Council of
Science and Public Health. He currently serves as a Medical
Consultant to the Federal Air Surgeon at the Federal Aviation
Administration. Dr. Gitlow obtained his MD at the Icahn School of
Medicine at Mount Sinai, completed
his psychiatric and public health training at University of Pittsburgh and a forensic psychiatry
fellowship at Harvard University.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. Our mission is
to be the global leader in the development and delivery of
treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the Company's
profile on SEDAR at www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-host-key-opinion-leader-webinar-on-substance-use-disorders-and-withdrawal-management-301545832.html
SOURCE Mind Medicine (MindMed) Inc.